This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pyrazolam
DrugBank Accession Number
DB14718
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 354.211
Monoisotopic: 353.027608
Chemical Formula
C16H12BrN5
Synonyms
  • Pirazolam

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Pyrazolam.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Pyrazolam.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Pyrazolam.
AclidiniumPyrazolam may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pyrazolam.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pyrazolam.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Pyrazolam.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pyrazolam.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Pyrazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pyrazolam.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8LH16383PK
CAS number
39243-02-2
InChI Key
BGRWSFIQQPVEML-UHFFFAOYSA-N
InChI
InChI=1S/C16H12BrN5/c1-10-20-21-15-9-19-16(13-4-2-3-7-18-13)12-8-11(17)5-6-14(12)22(10)15/h2-8H,9H2,1H3
IUPAC Name
12-bromo-3-methyl-9-(pyridin-2-yl)-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NN=C2CN=C(C3=CC=CC=N3)C3=C(C=CC(Br)=C3)N12

References

General References
Not Available
ChemSpider
15417688
ChEMBL
CHEMBL3246831
ZINC
ZINC000039247035
Wikipedia
Pyrazolam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0759 mg/mLALOGPS
logP1.76ALOGPS
logP2.36ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)18.38ChemAxon
pKa (Strongest Basic)2.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.96 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity99.17 m3·mol-1ChemAxon
Polarizability32.85 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at October 15, 2018 15:13 / Updated at June 12, 2020 16:53